Vaccines

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (BioNTech and Pfizer)

A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines.

Efficacy 95%

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

In this study, data from Israel’s largest health care organization were used to evaluate the effectiveness of the BNT162b2 mRNA vaccine.

Each study group included 596,618 persons.

Estimated vaccine effectiveness for the study outcomes at days 14 through 20 after the first dose and at 7 or more days after the second dose was as follows:

documented infection, 46% and 92%

symptomatic Covid-19, 57% and 94%

hospitalization, 74% and 87%

severe disease, 62% and 92%

Estimated effectiveness in preventing death from Covid-19 was 72% for days 14 through 20 after the first dose.

This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.

COVE mRNA-1273 (Moderna)

An mRNA Vaccine against SARS-CoV-2

Efficacy 95%

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2 (Oxford-AstraZeneca)